Absci Corporation

ABSI

Generative AIPrecision medicineBiotech & pharmaceuticals

$8.86vs prev close▼-0.69(-7.23%)

$2.2452W Range$12.05

67% from low

+1.32 (+17.46%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.70%

1M -0.14%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +2.5% · Market value -25.4% · Weight -0.14%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.23	BUY	ARKG	4,753	$8.07	$38.4K
26.07.21	BUY	ARKG	16,562	$8.32	$137.8K
26.07.20	BUY	ARKG	15,996	$8.16	$130.5K
26.07.17	BUY	ARKG	33,110	$8.30	$274.6K
26.07.16	BUY	ARKG	314,467	$8.23	$2.6M
26.07.15	SELL	ARKG	5,694	$9.76	$55.6K
26.07.14	SELL	ARKG	3,446	$10.23	$35.3K
26.07.13	SELL	ARKG	3,262	$10.21	$33.3K
26.07.09	SELL	ARKG	37,406	$11.47	$429.0K
26.07.08	SELL	ARKG	591	$11.10	$6.6K
26.07.07	SELL	ARKG	22,084	$11.33	$250.2K
26.07.06	SELL	ARKG	74,086	$11.54	$855.0K
26.07.02	SELL	ARKG	100,430	$11.62	$1.2M
26.07.01	SELL	ARKG	23,742	$11.11	$263.8K
26.06.30	SELL	ARKG	78,905	$11.59	$914.5K

07.23BUY

4,753

ARKGClose$8.07Est. total$38.4K

07.21BUY

16,562

ARKGClose$8.32Est. total$137.8K

07.20BUY

15,996

ARKGClose$8.16Est. total$130.5K

07.17BUY

33,110

ARKGClose$8.30Est. total$274.6K

07.16BUY

314,467

ARKGClose$8.23Est. total$2.6M

07.15SELL

5,694

ARKGClose$9.76Est. total$55.6K

07.14SELL

3,446

ARKGClose$10.23Est. total$35.3K

07.13SELL

3,262

ARKGClose$10.21Est. total$33.3K

07.09SELL

37,406

ARKGClose$11.47Est. total$429.0K

07.08SELL

591

ARKGClose$11.10Est. total$6.6K

07.07SELL

22,084

ARKGClose$11.33Est. total$250.2K

07.06SELL

74,086

ARKGClose$11.54Est. total$855.0K

07.02SELL

100,430

ARKGClose$11.62Est. total$1.2M

07.01SELL

23,742

ARKGClose$11.11Est. total$263.8K

06.30SELL

78,905

ARKGClose$11.59Est. total$914.5K

1 / 6

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

10,262,397

Portfolio Weight

0.7%

in ETF 5.2%

Est. Value

$86M

30D Net

+$3M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$13.89

vs Current ▲ +45.4% upside

Current$9.55

Low ~ High$10.00 ~ $17.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Needham

Buy

$11.00

+15.18%

—

Maintain

2026-08-12

BTIG

Buy

$13.00

+36.13%

—

Maintain

2026-08-12

Truist Securities

Buy

$17.00

+78.01%

—

Maintain

2026-07-02

HC Wainwright & Co.

Buy

$16.00

+67.54%

—

Maintain

2026-06-25

Needham

Buy

$11.00

+15.18%

—

Maintain

2026-06-24

1 / 4

Avg Target

$13.89

vs Current ▲ +45.4% upside

Strong Buy

10 analysts

Strong Buy 2Buy 7Hold 1

Low $10.00

Current $9.55

High $17.00

Firm	Position	Target	Upside	Close	Action	Date
Needham	Buy	$11.00	+15.18%	—	Maintain	26.08.12
BTIG	Buy	$13.00	+36.13%	—	Maintain	26.08.12
Truist Securities	Buy	$17.00	+78.01%	—	Maintain	26.07.02
HC Wainwright & Co.	Buy	$16.00	+67.54%	—	Maintain	26.06.25
Needham	Buy	$11.00	+15.18%	—	Maintain	26.06.24

1 / 4

Price Information

Previous Close$9.28

Open$9.56

Day Range$9.50 - $9.90

52-Week Range$2.24 - $12.05

1-Year Change275.98%

Trading Volume

Volume2,330,189

Avg Volume (3mo)5,077,114

Valuation

Market Cap1.6B

Book Value$1.44

Shares Outstanding171,614,010

Financials

Revenue (TTM)1.6M

Net Income-121,077,000

EPS$-0.79

EBITDA-119,506,000

Profitability

P/E Ratio-

P/B Ratio6.66

Return on Equity (ROE)-57.72%

Return on Assets (ROA)-34.09%

Profit Margin0.00%

EV/EBITDA-12.06

Beta2.42

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)66.80

Company Overview

Absci Corporation is a data-first generative AI drug creation company that uses AI and wet lab technologies to design antibody therapeutics. Their preclinical programs target various conditions including inflammatory bowel disease, alopecia, and oncology. Absci collaborates with several partners for joint research and development.

P/B

6.66

High valuation

ROE

-57.7%

Persistent loss

Beta

2.42

Extreme volatility

RSI(14)

66.8

Neutral zone

AI-generated summary. Not investment advice.

Absci Corporation

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks